RECRUITING

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Talk to us

Conditions

Relapsed Adult AMLPrimary Refractory Acute Myeloid LeukemiaHigh Risk Acute Myeloid LeukemiaCaregivers

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

Official Title

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Quick Facts

Study Start:2022-06-01
Study Completion:2029-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05237258

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 120 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patient Inclusion Criteria
  2. * Hospitalized patients (age ≥ 18 years) with high-risk AML defined as:
  3. * Patients with new diagnosis ≥ 60 years of age
  4. * An antecedent hematologic disorder
  5. * Therapy related-disease
  6. * Relapsed or primary refractory AML
  7. * Receiving treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or b) hypomethylating agents +/- additional agents or modification of this regimen on a clinical trial
  8. * Caregiver Inclusion Criteria
  9. * Adult (≥18 years) relative or friend of a participating patient who the patient identifies as living with or has in-person contact with them at least twice per week.
  1. * Patient Exclusion Criteria
  2. * Patients with a diagnosis of acute promyelocytic leukemia (APML)
  3. * Patients with AML receiving supportive care alone
  4. * Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures
  5. * Patients seen by a palliative care clinician \[MD or APP\] during two previous hospitalizations in the six months prior to enrollment

Contacts and Locations

Study Contact

Areej El-Jawahri, MD
CONTACT
617-724-4000
ael-jawahri@partners.org
Porsha L Lark, MS, MPH
CONTACT
PLark@mgh.harvard.edu

Principal Investigator

Areej El-Jawahri, MD
PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Jennifer Temel, MD
PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital

Study Locations (Sites)

University of Alabama - Birmingham
Birmingham, Alabama, 35294
United States
Stanford University
Stanford, California, 94305
United States
University of Colorado Denver I Anschutz Medical Campus
Denver, Colorado, 80204
United States
University of Miami
Miami, Florida, 33146
United States
Moffitt Cancer Center
Tampa, Florida, 33612
United States
Emory University
Atlanta, Georgia, 30322
United States
Northwestern University
Evanston, Illinois, 60208
United States
Indiana University
Bloomington, Indiana, 47405
United States
Johns Hopkins University
Baltimore, Maryland, 21218
United States
Massachusetts General Hospital
Boston, Massachusetts, 02115
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States
Mayo Clinic
Rochester, Minnesota, 55905
United States
University of Rochester
Rochester, New York, 14627
United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
United States
Duke University
Durham, North Carolina, 27708
United States
Ohio State University
Columbus, Ohio, 43210
United States
Oregon Health & Science University
Portland, Oregon, 97239
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
Fred Hutchinson Cancer Center
Seattle, Washington, 98109
United States
University of Wisconsin
Madison, Wisconsin, 53715
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

  • Areej El-Jawahri, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital
  • Jennifer Temel, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-01
Study Completion Date2029-04

Study Record Updates

Study Start Date2022-06-01
Study Completion Date2029-04

Terms related to this study

Keywords Provided by Researchers

  • Relapsed Adult AML
  • Primary Refractory Acute Myeloid Leukemia
  • High Risk Acute Myeloid Leukemia
  • Caregivers

Additional Relevant MeSH Terms

  • Relapsed Adult AML
  • Primary Refractory Acute Myeloid Leukemia
  • High Risk Acute Myeloid Leukemia